Speech treatment for Parkinson’s disease

References

• Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr. Logop.46, 9–17 (1994).
   PubMed Web of Science ®Google Scholar
• Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of people with Parkinson’s disease. Behav. Neurol.11, 131–137 (1998).
   PubMed Web of Science ®Google Scholar
• Logemann J, Fisher H, Boshes B, Blonsky E. Frequency and concurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson people. J. Speech Hear. Disord.43, 47–57 (1978).
   PubMedGoogle Scholar
• Pitcairn T, Clemie S, Gray J, Pentland B. Non-verbal cues in the self presentation of parkinsonian people. Br. J. Clin. Psychol.29, 177–184 (1990).
   PubMed Web of Science ®Google Scholar
• Pitcairn T, Clemie S, Gray J, Pentland B. Impressions of parkinsonian people from their recorded voices. Br. J. Clin. Psychol.25, 85–92 (1990).
   Google Scholar
• Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am. J. Speech. Lang. Pathol.2, 29–42 (1997).
   Google Scholar
• Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson’s disease. Age Ageing35(3), 235–239 (2006).
   PubMed Web of Science ®Google Scholar
• D’Amelio M, Ragonese P, Morgante L et al. Long-term survival of Parkinson’s disease: a population-based study. J. Neurol.253, 33–37 (2006).
   PubMed Web of Science ®Google Scholar
• Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson’s disease. Parkinsonism Relat. Disord.2, 41–50 (2001).
   Google Scholar
• Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson’s disease. Acta. Neurol. Scand.92, 55–58 (1995).
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan F, Kulad E, Cutson T, Schenkman M. The burden of Parkinson’s disease on society, family, and the individual. J. Am. Geriatr. Soc.45, 844–849 (1997).
   PubMed Web of Science ®Google Scholar
• Noyes K, Lui H, Li H, Holloway R, Dick AW. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov. Disord.3, 362–372 (2006).
   Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson’s disease. Mov. Disord.20, 1449–1454 (2005).
   PubMed Web of Science ®Google Scholar
• Baker K, Ramig LO, Johnson A, Freed C. Preliminary speech and voice analysis following fetal dopamine transplants in 5 people with Parkinson disease. J. Speech Hear. Res.20(3), 615–626 (1997).
   Google Scholar
• Ghika J, Ghika-Schmid F, Fankhauser H et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects, report of four cases and review of the literature. J. Neurosurg.9(2), 313–321 (1999).
   Google Scholar
• Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson’s disease. Neurology54, 458–462 (2000).
   PubMed Web of Science ®Google Scholar
• Larson K, Ramig LO, Scherer RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson’s disease. J. Med. Speech Lang. Pathol.2, 211–226 (1994).
   Google Scholar
• Rigrodsky S, Morrison EB. Speech changes in parkinsonism during l-dopa therapy: preliminary findings. J. Am. Geriatr. Soc.18, 142–151 (1970).
   PubMed Web of Science ®Google Scholar
• Wang E, Kompoliti K, Jiang J, Goetz CG. An instrumental analysis of laryngeal responses to apomorphine stimulation in Parkinson disease. J. Med. Speech Lang. Pathol.8, 175–186 (2002).
   Google Scholar
• Wolfe VI, Garvin JS, Bacon M, Waldrop W. Speech changes in Parkinson’s disease during treatment with l-dopa. J. Commun. Disord.8(3), 271–279 (1975).
   PubMed Web of Science ®Google Scholar
• Allan CM. Treatment of non-fluent speech resulting from neurological disease: treatment of dysarthria. Br. J. Disord. Commun.5, 3–5 (1970).
   PubMedGoogle Scholar
• Clinical Voice Disorders. Aronson AE (Ed.). Thieme-Stratton, NY, USA (1990).
   Google Scholar
• The Voice and Its Disorders. Greene HCL (Ed.). Pitman Medical, London, UK (1980).
   Google Scholar
• Sarno MT. Speech impairment in Parkinson’s disease. Arch. Phys. Med. Rehabil.49(5), 269–275 (1968).
   PubMedGoogle Scholar
• Weiner WJ, Singer C. Parkinson’s disease and nonpharmacologic treatment programs. J. Am. Geriatr. Soc.37, 359–363 (1989).
   PubMed Web of Science ®Google Scholar
• Oxtoby M. Parkinson’s Disease People and their Social Needs. Parkinson’s Disease Society, London, UK (1982).
   Google Scholar
• Baker K, Ramig LO, Luschei E, Smith M. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology51(6), 1592–1598 (1998).
   PubMed Web of Science ®Google Scholar
• Recent Advances in Clinical Dysarthria. Beukelman DR (Ed.) College-Hill Press, Boston, MA, USA. ( 1989).
   Google Scholar
• Leanderson R, Meyerson BA, Persson A. Effect of l-dopa on speech in parkinsonism an EMG study of labial articulatory function. J. Neurol. Neurosurg. Psychiatr.43, 679–681 (1971).
   Google Scholar
• Leanderson R, Meyerson BA, Persson A. Lip muscle function in parkinsonian dysarthria. Acta. Otolaryngol.74, 350–357 (1972).
   PubMed Web of Science ®Google Scholar
• Moore CA, Scudder RR. Coordination of jaw muscle activity in parkinsonian movement: description and response to traditional treatment. In: Recent Advances in Clinical Dysarthria. Yorkston KM, Beukelman DR (Eds). College-Hill Press, Boston, MA, USA.147–163 ( 1989).
   Google Scholar
• Yorkston KM. Treatment efficacy: dysarthria.J. Speech Hear. Res.39, S46–S57 (1996).
   PubMedGoogle Scholar
• Yorkston KM, Miller RM, Strand EA. Management of Speech and Swallowing in Degenerative Diseases. Communication Skill Builders, Tucson, AZ, USA ( 1997).
   Google Scholar
• Ackermann H, Ziegler W. Articulatory deficits in parkinsonian dysarthria. J. Neurol. Neurosurg. Psychiatr.54, 1093–1098 (1991).
   PubMed Web of Science ®Google Scholar
• Ackermann H, Konczak J, Hertrich I. The temporal control of repetitive articulatory movements in Parkinson’s disease. Brain Lang.56, 312–319 (1997).
   PubMed Web of Science ®Google Scholar
• Estenne M, Hubert M, Troyer AD. Respiratory-muscle involvement in Parkinson’s disease. N. Engl. J. Med.311, 1516–1517 (1984).
   PubMed Web of Science ®Google Scholar
• Hanson WR, Metter EJ. DAF Speech rate modification in Parkinson’s disease: a report of two cases. In: Clinical Dysarthria. Berry WR. (Ed.). College-Hill Press, San Diego, CA, USA ( 1983).
   Google Scholar
• Hoodin RB, Gilbert HR. Nasal airflows in parkinsonian speakers. J. Commun. Disord.22, 169–180 (1989).
   PubMed Web of Science ®Google Scholar
• Hoodin RB, Gilbert HR. Parkinsonian dysarthria: an aerodynamic and perceptual description of velopharyngeal closure for speech. Folia Phoniatr.41, 249–258 (1989).
   PubMed Web of Science ®Google Scholar
• Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain124, 2131–2146 (2001).
   PubMed Web of Science ®Google Scholar
• Desmurget M, Grafton ST, Vindras P, Grea H, Turner RS. The basal ganglia network mediates the planning of movement amplitude. Eur. J. Neurosci.19, 2871–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Turner RS, Anderson ME. Pallidal discharge related to the kinematics of reaching movements in two dimensions. J. Neurophysiol.77, 1051–1074 (1997).
   PubMed Web of Science ®Google Scholar
• Ho AK, Iansek R, Bradshaw JL. Regulations of parkinsonian speech volume: the effect of interlocuter distance. J. Neurol. Neurosurg. Psychiatr.67(2), 199–202 (1999).
   PubMed Web of Science ®Google Scholar
• Ho AK, Bradshaw JL, Iansek T. Volume perception in parkinsonian speech. Mov. Disord.15, 1125–1131 (2000).
   PubMed Web of Science ®Google Scholar
• Sapir S, Ramig L, Hoyt P, O’Brien C, Hoehn M. Phonatory–respiratory effort (LSVTÒ) vs respiratory effort treatment for hypokinetic dysarthria: comparing speech loudness and quality before and 12 months after treatment. Folia Phoniatr.54, 296–303 (2002).
   Web of Science ®Google Scholar
• Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson’s disease: effects of implicit cues and explicit instructions. Neuropsychologia37, 1453–1460 (1999).
   PubMed Web of Science ®Google Scholar
• Georgiou N, Iansek R, Bradshaw JL, Phillips JG, Mattingley JB, Bradshaw JA. An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia. Brain116, 1575–1587 (1993).
   PubMed Web of Science ®Google Scholar
• Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J. Speech Hear. Res.12, 462–469 (1969).
   PubMedGoogle Scholar
• Darley FL, Aronson A, Brown J. Differential diagnostic patterns of dysarthria. J. Speech Hear. Res.12, 246–269 (1969).
   PubMedGoogle Scholar
• Darley FL, Aronson AE, Brown JR. Motor Speech Disorders. WB Saunders, PA, USA ( 1975).
   Google Scholar
• Canter GJ. Speech characteristics of people with Parkinson’s disease: I. Intensity, pitch and duration. J. Speech Hear. Disord.28, 221–229 (1963).
   PubMedGoogle Scholar
• Canter GJ. Speech characteristics of people with Parkinson’s disease: III. Articulation, diadochokinesis and overall speech adequacy. J. Speech Hear. Disord.30, 217–224 (1965).
   PubMedGoogle Scholar
• Canter GJ. Speech characteristics of people with Parkinson’s disease: II. Physiological support for speech. J. Speech Hear. Disord.30, 44–49 (1965).
   PubMedGoogle Scholar
• Ludlow CL, Bassich CJ. Relationships between perceptual ratings and acoustic measures of hypokinetic speech. In: Dysarthria of Speech: Physiology-Acoustics-Linguistics-Management. McNeil MR, Rosenbek JC, Aronson AE (Eds). College-Hill Press, San Diego, CA, USA.163–196 (1983).
   Google Scholar
• Metter EJ, Hanson WR. Clinical and acoustical variability in hypokinetic dysarthria. J. Commun. Disord.19, 347–366 (1986).
   PubMed Web of Science ®Google Scholar
• Ho AK, Iansek R, Bradshaw JL. Motor instability in parkinsonian speech intensity. Neuropsychiatr. Neuropsychol. Behav. Neurol.14, 109–116 (2001).
   PubMedGoogle Scholar
• Fralle V, Cohen H. Prosody in Parkinson’s disease: relations between duration, amplitude and fundamental frequency range. Presented at: International Neuropsychological Society 23rd Annual Meeting. Seattle, WA, USA ( 1995).
   Google Scholar
• Logemann J, Fisher H, Boshes B, Blonsky E. Frequency and concurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J. Speech Hear. Disord.43, 47–57 (1978).
   PubMedGoogle Scholar
• Sapir S, Spielman J, Ramig L, Story B, Fox C. Effects of intensive voice treatment (LSVT®) on vowel articulation in dysarthric individuals with idiopathic Parkinson’s disease: acoustic and perceptual findings. J. Speech Lang. Hear. Res.50, 899–912 (2007).
   PubMed Web of Science ®Google Scholar
• Uziel A, Bohe M, Cadilhac J, Passouant P. Les troubles de la voix et de la parole dans les syndromes parkinson’siens. Folia Phoniatr.27(3), 166–176 (1975).
   PubMed Web of Science ®Google Scholar
• Weismer G. Articulatory characteristics of Parkinsonian dysarthria: segmental and phrase-level timing, spirantization and glottal-supraglottal coordination. In: The Dysarthrias: Physiology, Acoustics, Perception and Management. McNeil MR, Rosenbeck J, Aronson AE. (Eds). College Hill Press, San Diego, CA, USA. 101–130 ( 1984).
   Google Scholar
• Perez K, Ramig LO, Smith M, Dromey C. The parkinson larynx: tremor and videostroboscopic findings. J. Voice10, 354–361 (1996).
   PubMed Web of Science ®Google Scholar
• Smith M, Ramig LO, Dromey C, Perez K, Samandari R. Intensive voice treatment in Parkinson’s disease: laryngostroboscopic findings. J. Voice9, 453–459(1995).
   PubMed Web of Science ®Google Scholar
• Solomon N, Hixon TJ. Speech breathing in Parkinson’s disease. J. Speech Hear. Res.36, 294–310 (1993).
   PubMedGoogle Scholar
• Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J. Speech Lang Hear Res.44, 1284–1299 (2001).
   PubMed Web of Science ®Google Scholar
• Vincken W, Gauthier SG, Dollfuss RE, Hanson RE, Parauay CM, Cosio MG. Involvement of upper-airway muscles in extrapyramidal disorders, a cause of airflow limitation. N. Engl. J. Med.7(311), 438–442 (1984).
   Google Scholar
• Caligiuri M, Abbs JH. Response properties of the perioral reflex in Parkinson’s disease. Exp. Neurol.98, 563–572 (1987).
   PubMed Web of Science ®Google Scholar
• Hirose H. Pathophysiology of motor speech disorders (dysarthria). Folia Phoniat. (Basel)38, 61–88 (1986).
   PubMed Web of Science ®Google Scholar
• Leanderson R, Persson A, Ohman S. Electromyographic studies of the function of the facial muscles in dysarthria. Acta Otolaryngol. Suppl.263, 89–94 (1970).
   Google Scholar
• Rosen K, Kent RD, Duffy JR. Task-based profile of vocal intensity decline in Parkinson’s disease. Folia Phoniatr. Logop.57, 28–37(2005).
   PubMed Web of Science ®Google Scholar
• Sapir S, Pawlas AA, Ramig LO et al. Voice and speech abnormalities in Parkinson disease: relation to severity of motor impairment, duration of disease, medication, depression, gender, and age. J. Med. Speech Lang. Pathol.9, 213–226 (2001).
   Google Scholar
• Goberman A. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson disease. Med. Sci. Monit.11, CR109–CR116 (2005).
   PubMed Web of Science ®Google Scholar
• Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson’s disease. NeuroRehabilitation20, 205–221 (2005).
   PubMed Web of Science ®Google Scholar
• Diamond SG, Schneider JS, Markham CH. Oral sensorimotor defects in people with Parkinson’s disease. Adv. Neurol.45, 335–338 (1987).
   PubMedGoogle Scholar
• Schneider JS, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson’s disease. Ann. Neurol.19, 275–282 (1986).
   PubMed Web of Science ®Google Scholar
• Basal Ganglia and Behavior: Sensory Aspects of Motor Functioning. Schneider JS, Lidsky TI (Eds). Hans Huber, Toronto, Canada ( 1987).
   Google Scholar
• Graber S, Hertrich I, Daum I, Spieker S, Ackermann H. Speech perception deficits in Parkinson’s disease: underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang.82, 65–74 (2002).
   PubMed Web of Science ®Google Scholar
• Solomon NP, Robin DA, Lorell DM, Rodnitzky RL, Luschei ES. Tongue function testing in Parkinson’s disease: indicators of fatigue. In: Motor Speech Disorders: Advances in Assessment and Treatment. Till JA, Yorkston KM, Beukelman R. (Eds). Paul H. Brooks, Baltimore, MD, USA 147–160 ( 1994).
   Google Scholar
• Fox CM, Morrison CE, Ramig LO, Sapir S. Current perspectives on the Lee Silverman Voice Treatment (LSVT) for people with idiopathic Parkinson’s disease. Am. J. Speech. Lang. Pathol.11, 111–123 (2002).
   Web of Science ®Google Scholar
• Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson’s disease. Ann. Neurol.41, 781–788 (1997).
   PubMed Web of Science ®Google Scholar
• Jobst EE, Melnick ME, Byl NN, Dowling GA, Aminoff MJ. Sensory perception in Parkinson’s disease. Arch. Neurol.54, 450–454 (1997).
   PubMedGoogle Scholar
• Klockgether T, Borutta M, Rapp H, Spieder S, Dichgans J. A defect of kinesthesia in Parkinson’s disease. Brain120, 460–465 (1997).
   Google Scholar
• Rickards C, Cody FW. Proprioceptive control of wrist movements in Parkinson’s disease. Brain120, 977–990 (1997).
   PubMed Web of Science ®Google Scholar
• Oliveira RM, Gurd JM, Nixon P, Marshall JC, Passingham RE. Micrographia in Parkinson’s disease: the effect of providing external cues. J. Neurol. Neurosurg. Psychiatr.63(4), 429–433 (1997).
   PubMed Web of Science ®Google Scholar
• Schultz GM, Peterson T, Sapienza CM, Greer M, Friedman W. Voice and speech characteristics of persons with Parkinson’s disease pre- and post-pallidotomy surgery: preliminary findings. J. Speech Hear. Res.42, 1176–1194 (1999).
   Google Scholar
• Schultz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson’s disease: a review of the literature. J. Commun. Disord.33, 59–88 (2000).
   PubMed Web of Science ®Google Scholar
• Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson’s disease. Lancet Neurol.3, 547–556 (2004).
   PubMed Web of Science ®Google Scholar
• No authors listed. Speech therapy in Parkinson’s disease. Mov. Disord.17(4), S163–S166 (2002).
   Google Scholar
• Yorkston KM, Spencer KA, Duffy JR. Behavioral management of respiratory/ phonatory dysfunction from dysarthria: a systematic review of the evidence. J. Med. Speech Lang. Pathol.11, xiii–xxxviii ( 2003).
   Web of Science ®Google Scholar
• Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment [LSVT®] for voice, speech, and other orofacial disorders in people with Parkinson’s disease. Future Neurol.1, 563–570 (2006).
   Google Scholar
• Radad K, Gille G, Rausch W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol. Rep.57, 701–712 (2005).
   PubMed Web of Science ®Google Scholar
• De Letter M, Santens P, Van Borsel J. The effects of levodopa on word intelligibility in Parkinson’s disease. J. Commun. Disord.38, 187–196 (2005).
   PubMed Web of Science ®Google Scholar
• Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J. Commun. Disord.35, 217–239 (2002).
   PubMed Web of Science ®Google Scholar
• Sanabria J, Ruiz PG, Gutierrez R et al. The effect of levodopa on vocal function in Parkinson’s disease. Clin. Neuropharmacol.24, 99–102 (2001).
   PubMed Web of Science ®Google Scholar
• Cahill L, Murdoch BE, Theodoros DG, Triggs EJ, Charles BG, Yao AA. Effect of oral levodopa treatment on articulatory function in Parkinson’s disease: preliminary results. Motor Control2, 161–172 (1998).
   PubMedGoogle Scholar
• Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson’s disease. Laryngoscope109, 1287–1294 (1999).
   PubMed Web of Science ®Google Scholar
• Biary N, Pimental PA, Langenberg PW. A double-blind trial of clonazepan in the treatment of parkinsonian dysarthria. Neurology38(2), 255–258 (1988).
   PubMed Web of Science ®Google Scholar
• Krack P, Batir A, VanBiercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.20, 1925–1934 (2003).
   Google Scholar
• Witt K, Pulkowski U, Herzog J et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch. Neurol.61, 697–700 (2004).
   PubMedGoogle Scholar
• D’Alatri L, Paludetti G, Contarino MF, Galla S, Marchese MR, Bentivoglio AR. Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment. J. Voice (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Klostermann F, Ehlen F, Vesper J et al. Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. (2007) (In Press).
   PubMed Web of Science ®Google Scholar
• Törnqvist AL, Schalén L, Rehncrona S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson’s disease treated with subthalamic deep brain stimulation.Mov. Disord.20, 416–423 (2005).
   PubMed Web of Science ®Google Scholar
• Deane KHO, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy for dysarthria in Parkinson’s disease: a comparison of techniques (Cochrane Review). The Cochrane Library (Issue 2) John Wiley & Sons, Ltd., Chichester, UK ( 2004).
   Google Scholar
• Dean KHO, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy versus placebo or no intervention for dysarthria in Parkinson’s disease. The Cochrane Library (Issue 2). John Wiley & Sons, Ltd., Chichester, UK ( 2004).
   Google Scholar
• NICE, National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, London, UK ( 2006).
   Google Scholar
• Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T. Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease. Neurology66, 976–982 (2006).
   PubMed Web of Science ®Google Scholar
• Ramig LO, Countryman S, O’Brien C, Hoehn M, Thompson L. Intensive speech treatment for people with Parkinson’s disease: short and long term comparison of two techniques. Neurology47, 1496–1504 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson J, Pring T. Speech therapy and Parkinson’s disease: a review and further data. Br. J. Disord. Commun.125, 183–194 (1990).
   Google Scholar
• Scott S, Caird FL. Speech therapy for Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.46, 140–144 (1983).
   PubMed Web of Science ®Google Scholar
• Ramig LO, Sapir S, Countryman S et al. Intensive voice treatment (LSVT®) for people with Parkinson’s disease: a 2 year follow-up. J. Neurol. Neurosurg. Psychiatr.71, 493–498 (2001).
   PubMed Web of Science ®Google Scholar
• Ramig L, Sapir S, Fox C, Countryman S. Changes in vocal intensity following intensive voice treatment (LSVT®) in people with Parkinson disease: a comparison with untreated people and with normal age-matched controls. Mov. Disord.16, 79–83 (2001).
   PubMed Web of Science ®Google Scholar
• Montgomery EB, Turkstra LS. Evidence-based practice: let’s be reasonable. J. Med. Speech Lang. Pathol.11(2), ix–xii ( 2003).
   Google Scholar
• Yorkston KM, Hakel, M, Beukelman DR, Fager S. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J. Med. Speech Lang. Pathol.15(2), xi–xxxvi ( 2007).
   Google Scholar
• Robey RR, Schultz MC. A model for conducting clinical-outcome research: an adaptation of the standard protocol for use in aphasiology. Aphasiology.12, 787–810 (1998).
   Web of Science ®Google Scholar
• Albin RL, Young AB, Penny JB. The functional anatomy of basal ganglia disorders. Trends Neurosci.12, 366–375 (1989).
   PubMed Web of Science ®Google Scholar
• Barbeau A, Sourkes TL, Murphy CF. Les catecholamines de la maladie de Parkinson’s. In: Monoamines et Systeme Nerveux Central. Ajuriaguerra J. (Ed.).George, Geneve, Switzerland.247–262 ( 1962).
   Google Scholar
• Penny JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu. Rev. Neurosci.6, 73–94 (1983).
   PubMed Web of Science ®Google Scholar
• Berardelli A, Dick JP, Rothwell JC, Day BL, Marsden CD. Scaling of the size of the first agonist EMG burst during rapid wrist movements in people with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.49(11), 1273–1279 (1986).
   PubMed Web of Science ®Google Scholar
• Demirci M, Grill S, McShane L, Hallet M. Impairment of kinesthesia in Parkinson’s disease. Neurology45, A218 ( 1995).
   Google Scholar
• Stelmach GE. Basal ganglia impairment and force control. In: Tutorial in Motor Neuroscience. Requin J, Stelmach GE. (Eds). Kluwer Academic Publishers, The Netherlands. 147–158 (1991).
   Google Scholar
• Fisher B, Petzinger G, Nixon K et al. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J. Neurosci. Res.77, 378–390 (2004).
   PubMed Web of Science ®Google Scholar
• Liepert J, Miltner W, Bauder H et al. Motor cortex plasticity during constraint-induced movement therapy in stroke patients. Neurosci. Lett.250, 5–8 (1998).
   PubMed Web of Science ®Google Scholar
• Kleim J, Jones T, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury, Neurochem. Res.11, 1757–1769 (2003).
   Google Scholar
• Liotti M, Ramig LO, Vogel D et al. Hypophonia in Parkinson’s disease. Neural correlates of voice treatment revealed by PET. Neurology60, 432–440 (2003).
   PubMed Web of Science ®Google Scholar
• Fox C, Ramig L, Ciucci M, Sapir S, McFarland D, Farley B. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin. Speech Lang.27(4), 283–299 (2006)
   PubMedGoogle Scholar
• Taub E. Harnessing brain plasticity through behavioral techniques to produce new treatments in neurorehabilitation. Am. Psychol.59(8), 692–704 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher B, Yip J. Physical therapy for individuals with Parkinson’s disease: a paradigm shift. Parkinson ReportXVI(2), 10–13 ( 2005).
   Google Scholar
• Dromey C, Ramig L. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J. Speech Lang. Hear. Res.41, 1003–1018 (1998).
   PubMed Web of Science ®Google Scholar
• Allen G. Segmental timing control in speech production. J. Phon.1, 219–237 (1973).
   Google Scholar
• Gandour J, Dechongkit S, Ponglorpisit S, Khunadorn F. Speech timing at the sentence level in Thai after unilateral brain damage. Brain Lang.46, 419–438 (1994).
   PubMed Web of Science ®Google Scholar
• McClean MD, Tasko SM. Association of orofacial with laryngeal and respiratory motor output during speech. Exp. Brain Res.146, 481–489 (2002).
   PubMed Web of Science ®Google Scholar
• Ackermann H, Wildgruber D, Daum I, Grodd W. Does the cerebellum contribute to cognitive aspects of speech production? A functional magnetic resonance imaging (fMRI) study in humans. Neurosci. Lett.247, 187–190 (1998).
   PubMed Web of Science ®Google Scholar
• Hirano S, Kojima H, Naito Y et al. Cortical speech processing mechanisms while vocalizing visually presented languages. Neuroreport.8, 363–367 (1996).
   PubMed Web of Science ®Google Scholar
• Jurgens U, Kirzinger A, von Cramon D. The effects of deep-reaching lesions in the cortical face area on phonation. A combined case report and experimental monkey study. Cortex18, 125–130 (1982).
   PubMed Web of Science ®Google Scholar
• Kitchen DM, Cheney DL, Seyfarth RM. Male chacma baboons (Papio hamadryas ursinus) discriminate loud call contests between rivals of different relative ranks. Anim. Cogn8, 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Leinonen L, Laakso ML, Carlson S, Linnankoski I. Shared means and meanings in vocal expression of man and macaque. Logoped. Phoniatr. Vocol.28, 53–61 (2003).
   PubMedGoogle Scholar
• Tecumseh W. The phonetic potential of nonhuman vocal tracts: comparative cineradiographic observations of vocalizing animals. Phonetica57, 205–218 (2000).
   PubMed Web of Science ®Google Scholar
• Narayana S, Vogel D, Brown S et al. Mechanism of action of voice therapy in Parkinson’s hypophonia – A PET study. Presented at: 11th Annual Meeting of the Organization for Human Brain Mapping. Toronto, Ontario, Canada, 12–16 June 2005.
   Google Scholar
• Dobkins BH. Confounders in rehabilitation trials of task-oriented training: lessons from the designs of the EXCITE and SCILT multicenter trials. Neurorehabil. Neural Repair.21(1), 3–13 (2007).
   PubMed Web of Science ®Google Scholar
• Duncan S. Preliminary data on effects of behavioral and levadopa therapies of speech-accompanying gesture in Parkinson’s disease. Presented at: ICSLP Meeting. Denver, CO, USA, 16–20 September 2002.
   Google Scholar
• El Sharkawi A, Ramig LO, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J. Neurol. Neurosurg. Psychiatr.71, 31–36 (2002).
   Google Scholar
• Ramig LO, Bonitati C, Lemke J, Horii Y. Voice treatment for people with Parkinson disease: development of an approach and preliminary efficacy data. J. Med. Speech Lang. Pathol.2, 191–209 (1994).
   Google Scholar
• Ramig LO, Dromey C, Johnson A, Scherer R. The effects of phonatory, respiratory and articulatory effect treatment on speech and voice in Parkinson’s disease. Presented at: Motor Speech Conference, Sedona AZ, April 1994.
   Google Scholar
• Farley BF, Koshland CF, Prior MM. Learning big decreases bradykinesia in the upper and lower limbs in people with Parkinson’s disease. Presented at: Annual Society for Neuroscience Meeting. San Diego, CA, USA, 23–27 October 2004.
   Google Scholar
• Farley B, Koshland G. Efficacy of a large-amplitude exercise approach for patients with Parkinson’s disease – bradykinesia to balance. Presented at: 9th International Congress of Parkinson’s Disease and Movement Disorders. New Orleans, LA, USA, 5–8 March 2005.
   Google Scholar
• Fox CM, Farley BG, Ramig LO, McFarland D. An integrated rehabilitation approach to Parkinson’s disease: learning big and loud. Mov. Disord.20(10), S127 ( 2005).
   Google Scholar
• Fox CM, Farley BG, Ramig LO, McFarland D. An integrated speech and physical therapy approach for Parkinson’s disease: training big and loud. Mov. Disord.22(16), S98–S99 (2007).
   Google Scholar
• Ramig L, Countryman S, Thompson L, Horii Y. Comparison of two forms of intensive speech treatment for Parkinson disease. J. Speech Hear. Res.38, 1232–1251 (1995).
   PubMedGoogle Scholar
• Ciucci MR, Ma TS, Fox CM, Kane J, Ramig L, Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav. Brain Res.182, 284–289 (2007).
   PubMed Web of Science ®Google Scholar
• Taub E, Lum PS, Hardin P, Mark BW, Uswatte G. AutoCITE: automated delivery of CI therapy with reduced effort by therapists. Stroke.36, 1301–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Halpern AE, Matos C, Ramig LO, Petska J, Spielman J. LSVTC – a PDA supported speech treatment for Parkinson’s disease. Presented at: Annual American Speech-Language-Hearing Association Meeting. Philadelphia, PA, USA 17–22 July 2004.
   Google Scholar
• Halpern A, Matos C, Ramig L, Petska J, Spielman J, Bennett J. LSVTC – A PDA supported speech treatment for Parkinson’s disease. Presented at: 9th International Congress of Parkinson’s Disease and Movement Disorders. New Orleans, LA, USA 5–8 March 2005.
   Google Scholar
• Ramig LO, Pawlas A, Countryman S. The Lee Silverman Voice Treatment (LSVT): A Practical Guide to Treating the Voice and Speech Disorders in Parkinson Disease. National Center for Voice and Speech, IA, USA (1995).
   Google Scholar